HRP20201353T1 - Agonisti glukagonskog receptora - Google Patents
Agonisti glukagonskog receptora Download PDFInfo
- Publication number
- HRP20201353T1 HRP20201353T1 HRP20201353TT HRP20201353T HRP20201353T1 HR P20201353 T1 HRP20201353 T1 HR P20201353T1 HR P20201353T T HRP20201353T T HR P20201353TT HR P20201353 T HRP20201353 T HR P20201353T HR P20201353 T1 HRP20201353 T1 HR P20201353T1
- Authority
- HR
- Croatia
- Prior art keywords
- glucagon receptor
- seq
- agonist
- glp
- receptor agonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562246199P | 2015-10-26 | 2015-10-26 | |
| EP16785667.3A EP3368060B1 (en) | 2015-10-26 | 2016-10-14 | Glucagon receptor agonists |
| PCT/US2016/056959 WO2017074714A1 (en) | 2015-10-26 | 2016-10-14 | Glucagon receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201353T1 true HRP20201353T1 (hr) | 2020-11-27 |
Family
ID=57200152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201353TT HRP20201353T1 (hr) | 2015-10-26 | 2016-10-14 | Agonisti glukagonskog receptora |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US9764004B2 (https=) |
| EP (2) | EP3368060B1 (https=) |
| JP (3) | JP6321299B2 (https=) |
| KR (1) | KR20180053747A (https=) |
| CN (2) | CN108348583B (https=) |
| AR (2) | AR106318A1 (https=) |
| AU (2) | AU2016344433B2 (https=) |
| BR (1) | BR112018006920A2 (https=) |
| CA (2) | CA3000538A1 (https=) |
| DK (1) | DK3368060T3 (https=) |
| EA (2) | EA201890676A1 (https=) |
| ES (2) | ES2809548T3 (https=) |
| HR (1) | HRP20201353T1 (https=) |
| HU (1) | HUE050859T2 (https=) |
| IL (1) | IL258092A (https=) |
| LT (1) | LT3368060T (https=) |
| MX (2) | MX377610B (https=) |
| NZ (1) | NZ740644A (https=) |
| PL (2) | PL3368061T3 (https=) |
| PT (2) | PT3368060T (https=) |
| RS (1) | RS60567B1 (https=) |
| SI (1) | SI3368060T1 (https=) |
| TW (1) | TWI622596B (https=) |
| WO (2) | WO2017074714A1 (https=) |
| ZA (2) | ZA201801756B (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10570184B2 (en) | 2014-06-04 | 2020-02-25 | Novo Nordisk A/S | GLP-1/glucagon receptor co-agonists for medical use |
| TWI622596B (zh) * | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| UA127495C2 (uk) | 2015-12-23 | 2023-09-13 | Амджен Інк. | Виділений антигензв'язуючий білок, який специфічно зв'язується з поліпептидом рецептора шлункового інгібіторного пептиду (gipr) людини, та фармацевтична композиція, яка його містить |
| IL313587A (en) | 2017-01-17 | 2024-08-01 | Amgen Inc | Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr) |
| EA201992502A1 (ru) | 2017-06-20 | 2020-04-22 | Эмджен Инк. | Способ лечения или уменьшения интенсивности метаболических нарушений с применением белков, связывающих рецептор гастроингибиторного пептида (gipr), в комбинации с агонистами glp-1 |
| EP3642238A1 (en) * | 2017-06-21 | 2020-04-29 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteins |
| US11352405B2 (en) * | 2017-08-09 | 2022-06-07 | Sanofi | GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis |
| EP3684793A1 (en) | 2017-09-22 | 2020-07-29 | Regeneron Pharmaceuticals, Inc. | Glucagon-like peptide 1 receptor agonists and uses thereof |
| AR113486A1 (es) * | 2017-12-21 | 2020-05-06 | Lilly Co Eli | Análogos de incretina y sus usos |
| WO2019140021A1 (en) * | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Combination therapy |
| WO2019140025A1 (en) * | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Combination therapy |
| WO2019140024A1 (en) | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Combination therapy |
| CN119499352A (zh) * | 2018-07-23 | 2025-02-25 | 伊莱利利公司 | 使用gip/glp1共激动剂用于糖尿病的方法 |
| KR20240051304A (ko) * | 2018-07-23 | 2024-04-19 | 일라이 릴리 앤드 캄파니 | Gip/glp1 공효능제 화합물 |
| WO2020071865A1 (ko) * | 2018-10-04 | 2020-04-09 | 한미약품 주식회사 | 글루카곤 및 이를 포함하는 조합물의 치료학적 용도 |
| SG11202103137WA (en) * | 2018-10-26 | 2021-04-29 | Novo Nordisk As | Stable semaglutide compositions and uses thereof |
| EP3882263A4 (en) * | 2018-11-12 | 2022-08-31 | Tianjin Institute Of Pharmaceutical Research Co., Ltd. | GLUCAGON DERIVED PEPTIDE AND USE THEREOF |
| TWI799680B (zh) * | 2019-01-29 | 2023-04-21 | 美商美國禮來大藥廠 | 製備gip/glp1雙重促效劑之方法 |
| US20200268835A1 (en) * | 2019-02-27 | 2020-08-27 | Novo Nordisk A/S | Compounds For Use in NASH |
| WO2020190591A1 (en) * | 2019-03-15 | 2020-09-24 | Eli Lilly And Company | Preserved formulations |
| DK3936142T3 (da) * | 2019-06-28 | 2024-03-25 | Hanmi Pharmaceutical Co Ltd | Tredobbelt agonist med aktivitet med hensyn til alle glucagon-, GLP-1- og GLP-receptorer til behandling af leversygdom |
| CN110684082B (zh) * | 2019-10-08 | 2021-12-10 | 江苏诺泰澳赛诺生物制药股份有限公司 | Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途 |
| JP7761567B2 (ja) * | 2020-02-18 | 2025-10-28 | ノヴォ ノルディスク アー／エス | 医薬製剤 |
| TW202216746A (zh) | 2020-06-22 | 2022-05-01 | 印度商太陽製藥工業有限公司 | 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑 |
| PE20231309A1 (es) | 2020-10-17 | 2023-08-24 | Sun Pharmaceutical Ind Ltd | Agonistas duales glp-1/gip |
| CA3204051A1 (en) | 2021-01-20 | 2022-07-28 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| US12281149B2 (en) | 2021-05-13 | 2025-04-22 | Carmot Therapeutics, Inc. | Modulators of G-protein coupled receptors |
| JP7642830B2 (ja) | 2021-09-15 | 2025-03-10 | バイキング・セラピューティクス・インコーポレイテッド | 代謝及び肝臓障害の処置のための組成物及び方法 |
| WO2024064842A1 (en) | 2022-09-21 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Methods of treating obesity, diabetes, and liver dysfunction |
| EP4687947A1 (en) | 2023-04-05 | 2026-02-11 | Antag Therapeutics ApS | Gip activity modulators and orthostatic intolerance |
| KR20260022948A (ko) | 2023-06-09 | 2026-02-20 | 썬 파마슈티컬 인더스트리스 리미티드 | Glp-1/gip 이중 수용체 작용제, glp-1/gcg 이중 수용체 작용제, 및 glp-1/gip/gcg 삼중 수용체 작용제 |
| CN120349392A (zh) * | 2023-11-06 | 2025-07-22 | 成都奥达生物科技有限公司 | 一种gip激动剂化合物 |
| US20250352622A1 (en) | 2024-05-15 | 2025-11-20 | Rose Pharma Inc. | Glp-1 formulations and their uses |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6004932A (en) | 1997-03-06 | 1999-12-21 | Iowa State University Research Foundation, Inc. | Use of glucagon as a metabolic conditioner for dairy cows and other ruminants |
| DK1641823T3 (da) | 2003-06-12 | 2011-12-12 | Lilly Co Eli | GLP-1-analog fusionsproteiner |
| AU2005203925A1 (en) * | 2004-01-08 | 2005-07-21 | Theratechnologies Inc. | Glucagon-Like Peptide-1 analogs with long duration of action |
| RU2477286C2 (ru) | 2007-01-05 | 2013-03-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH |
| CA2677932A1 (en) * | 2007-02-15 | 2008-08-21 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| EP2249853A4 (en) | 2008-01-30 | 2012-12-26 | Univ Indiana Res & Tech Corp | ESTER BASED PEPTIDE PRODRUGS |
| CN102105159B (zh) | 2008-06-17 | 2015-07-08 | 印第安纳大学研究及科技有限公司 | 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症 |
| AR072160A1 (es) | 2008-06-17 | 2010-08-11 | Univ Indiana Res & Tech Corp | Co-agonistas del receptor de glucagon/glp-1 |
| US8450270B2 (en) | 2008-06-17 | 2013-05-28 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers |
| ES2477880T3 (es) * | 2008-12-15 | 2014-07-18 | Zealand Pharma A/S | Análogos del glucagón |
| PE20120332A1 (es) | 2008-12-19 | 2012-04-14 | Univ Indiana Res & Tech Corp | Profarmacos de peptido de la superfamilia de glucagon basado en amida |
| EP2443146B1 (en) | 2009-06-16 | 2016-10-05 | Indiana University Research And Technology Corporation | Gip receptor-active glucagon compounds |
| AU2010272944B2 (en) | 2009-07-13 | 2015-11-19 | Zealand Pharma A/S | Acylated glucagon analogues |
| US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| JO2976B1 (en) | 2009-12-22 | 2016-03-15 | ايلي ليلي اند كومباني | Axentomodulin polypeptide |
| AR079344A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad |
| AR080592A1 (es) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
| EP2552951A1 (en) | 2010-03-26 | 2013-02-06 | Novo Nordisk A/S | Novel glucagon analogues |
| EP2560675A1 (en) * | 2010-04-20 | 2013-02-27 | Novo Nordisk A/S | Long-acting gastrin derivatives |
| JP6050746B2 (ja) | 2010-05-13 | 2016-12-21 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | Ｇタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド |
| KR101382593B1 (ko) | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
| US8507428B2 (en) | 2010-12-22 | 2013-08-13 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
| WO2012088379A2 (en) | 2010-12-22 | 2012-06-28 | Marcadia Biotech, Inc. | Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides |
| KR20140043709A (ko) | 2011-01-20 | 2014-04-10 | 질랜드 파마 에이/에스 | 아실화 글루카곤 유사체와 인슐린 유사체의 조합 |
| RU2013145013A (ru) | 2011-03-28 | 2015-05-10 | Ново Нордиск А/С | Новые аналоги глюкагона |
| DK2694095T3 (en) | 2011-04-05 | 2018-05-28 | Longevity Biotech Inc | COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME |
| RS56173B1 (sr) | 2011-06-22 | 2017-11-30 | Univ Indiana Res & Tech Corp | Koagonisti receptora za glukagon/glp-1 receptora |
| KR20140043793A (ko) | 2011-06-22 | 2014-04-10 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루카곤/glp-1 수용체 공동-작용물질 |
| WO2013004983A1 (en) * | 2011-07-04 | 2013-01-10 | Imperial Innovations Limited | Novel compounds and their effects on feeding behaviour |
| AU2012311484B2 (en) | 2011-09-23 | 2017-04-13 | Novo Nordisk A/S | Novel glucagon analogues |
| IN2014CN04401A (https=) * | 2011-12-23 | 2015-09-04 | Zealand Pharma As | |
| IN2014MN02304A (https=) | 2012-05-03 | 2015-08-07 | Zealand Pharma As | |
| CN104583232B (zh) | 2012-06-21 | 2018-04-13 | 印第安纳大学研究及科技有限公司 | 展现gip受体活性的胰高血糖素类似物 |
| PE20150863A1 (es) | 2012-06-21 | 2015-06-11 | Univ Indiana Res & Tech Corp | Analogos de glucagon que exhiben actividad de receptor de gip |
| IN2015DN00544A (https=) * | 2012-07-23 | 2015-06-26 | Zealand Pharma As | |
| WO2014041375A1 (en) | 2012-09-17 | 2014-03-20 | Imperial Innovations Limited | Peptide analogues of glucagon and glp1 |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| TWI617574B (zh) * | 2012-12-11 | 2018-03-11 | 梅迪繆思有限公司 | 用於治療肥胖之升糖素與ｇｌｐ－１共促效劑 |
| AU2013366692B2 (en) | 2012-12-21 | 2017-11-23 | Sanofi | Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists |
| EP2986313B1 (en) | 2013-04-18 | 2019-06-12 | Novo Nordisk A/S | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
| JP6230352B2 (ja) | 2013-09-19 | 2017-11-15 | ユニ・チャーム株式会社 | 動物用排泄物処理材の製造方法および製造装置 |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| PL3057984T3 (pl) | 2013-10-17 | 2018-12-31 | Zealand Pharma A/S | Acylowane analogi glukagonu |
| WO2015067715A2 (en) | 2013-11-06 | 2015-05-14 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| CN105829339B (zh) | 2013-11-06 | 2021-03-12 | 西兰制药公司 | 胰高血糖素-glp-1-gip三重激动剂化合物 |
| US20150150643A1 (en) * | 2013-12-02 | 2015-06-04 | The Johns Hopkins University | Personalized computational modeling of atrial fibrosis to guide catheter ablation of atrial fibrillation |
| TW201609800A (zh) * | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 做為雙重ｇｌｐ－１／升糖素受體促效劑之艾塞那肽－４胜肽類似物 |
| WO2015086733A1 (en) * | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| EP3080154B1 (en) * | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| AR098614A1 (es) | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Compuesto para el tratamiento de hipoglicemia severa |
| AR098615A1 (es) | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Péptido para el tratamiento de hipoglicemia severa |
| AR098616A1 (es) | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Péptido para el tratamiento de hipoglicemia severa |
| MX2016010599A (es) * | 2014-02-18 | 2016-11-18 | Novo Nordisk As | Analogos de glucagon estables y uso para el tratamiento de hipoglucemia. |
| TW201625669A (zh) * | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| TWI802396B (zh) | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
| PE20171154A1 (es) | 2014-12-30 | 2017-08-16 | Hanmi Pharm Ind Co Ltd | Derivados de glucagon con estabilidad mejorada |
| TWI582109B (zh) | 2015-01-09 | 2017-05-11 | 美國禮來大藥廠 | Ｇｉｐ及ｇｌｐ－１共促效劑化合物 |
| DK3283507T3 (da) | 2015-04-16 | 2020-01-02 | Zealand Pharma As | Acyleret glucagonanalog |
| WO2016198604A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as dual glp-1 /glucagon receptor agonists |
| EP4523705A3 (en) | 2015-06-30 | 2025-06-11 | Hanmi Pharm. Co., Ltd. | Glucagon derivative and a composition comprising a long acting conjugate of the same |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| TWI622596B (zh) * | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
-
2016
- 2016-10-07 TW TW105132649A patent/TWI622596B/zh not_active IP Right Cessation
- 2016-10-11 AR ARP160103103A patent/AR106318A1/es unknown
- 2016-10-12 AR ARP160103112A patent/AR106325A1/es unknown
- 2016-10-14 KR KR1020187011338A patent/KR20180053747A/ko not_active Abandoned
- 2016-10-14 CN CN201680062467.6A patent/CN108348583B/zh active Active
- 2016-10-14 ES ES16785667T patent/ES2809548T3/es active Active
- 2016-10-14 CA CA3000538A patent/CA3000538A1/en not_active Abandoned
- 2016-10-14 PT PT167856673T patent/PT3368060T/pt unknown
- 2016-10-14 PL PL16785669T patent/PL3368061T3/pl unknown
- 2016-10-14 EP EP16785667.3A patent/EP3368060B1/en active Active
- 2016-10-14 ES ES16785669T patent/ES2747908T3/es active Active
- 2016-10-14 EA EA201890676A patent/EA201890676A1/ru unknown
- 2016-10-14 WO PCT/US2016/056959 patent/WO2017074714A1/en not_active Ceased
- 2016-10-14 NZ NZ74064416A patent/NZ740644A/en unknown
- 2016-10-14 EA EA201890634A patent/EA038330B1/ru unknown
- 2016-10-14 LT LTEP16785667.3T patent/LT3368060T/lt unknown
- 2016-10-14 PL PL16785667T patent/PL3368060T3/pl unknown
- 2016-10-14 MX MX2018005129A patent/MX377610B/es active IP Right Grant
- 2016-10-14 US US15/293,324 patent/US9764004B2/en active Active
- 2016-10-14 PT PT167856699T patent/PT3368061T/pt unknown
- 2016-10-14 JP JP2017531687A patent/JP6321299B2/ja active Active
- 2016-10-14 MX MX2018005132A patent/MX2018005132A/es unknown
- 2016-10-14 BR BR112018006920-5A patent/BR112018006920A2/pt not_active Application Discontinuation
- 2016-10-14 CA CA3003242A patent/CA3003242C/en active Active
- 2016-10-14 AU AU2016344433A patent/AU2016344433B2/en not_active Ceased
- 2016-10-14 US US15/293,316 patent/US9884093B2/en active Active
- 2016-10-14 HU HUE16785667A patent/HUE050859T2/hu unknown
- 2016-10-14 DK DK16785667.3T patent/DK3368060T3/da active
- 2016-10-14 HR HRP20201353TT patent/HRP20201353T1/hr unknown
- 2016-10-14 RS RS20200896A patent/RS60567B1/sr unknown
- 2016-10-14 EP EP16785669.9A patent/EP3368061B1/en active Active
- 2016-10-14 SI SI201630840T patent/SI3368060T1/sl unknown
- 2016-10-14 WO PCT/US2016/056969 patent/WO2017074715A1/en not_active Ceased
- 2016-10-14 JP JP2017531685A patent/JP6354017B2/ja active Active
- 2016-10-14 CN CN201680062196.4A patent/CN108135981B/zh active Active
- 2016-10-14 AU AU2016344434A patent/AU2016344434B2/en active Active
-
2017
- 2017-12-22 US US15/851,762 patent/US20180104312A1/en not_active Abandoned
-
2018
- 2018-03-13 IL IL258092A patent/IL258092A/en unknown
- 2018-03-14 ZA ZA201801756A patent/ZA201801756B/en unknown
- 2018-04-04 JP JP2018072110A patent/JP7211712B2/ja active Active
- 2018-04-11 ZA ZA2018/02371A patent/ZA201802371B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201353T1 (hr) | Agonisti glukagonskog receptora | |
| JP2018135346A5 (https=) | ||
| PE20220938A1 (es) | Compuestos agonistas de gipr | |
| HRP20191614T1 (hr) | Spojevi koji su suagonisti gip i glp-1 | |
| ES2558330T3 (es) | Péptido WT1 restringido por HLA-A*3303 y composición farmacéutica que comprende el mismo | |
| NZ737050A (en) | Glucagon and glp-1 co-agonist compounds | |
| HRP20170890T1 (hr) | Suagonisti glukagonskog/glp-1 receptora | |
| HRP20140616T1 (hr) | Peptidni analog oksintomodulina | |
| JP2018515088A5 (https=) | ||
| PE20241305A1 (es) | Analogos de amilina | |
| AU2025202650A1 (en) | ELP fusion proteins for controlled and sustained release | |
| JP2014525901A5 (https=) | ||
| MY199821A (en) | Modified lipidated relaxin b chain peptides and their therapeutic use | |
| JP2014524908A5 (https=) | ||
| RU2017146657A (ru) | Пролекарства, содержащие коньюгат гиалуроновой кислоты, ликера и и двойного агониста glp-1глюкагона | |
| CA2965560A1 (en) | Compositions and peptides having dual glp-1r and glp-2r agonist activity | |
| AR072159A1 (es) | Analogos de glucagon, basados en (peptido insulinotropico dependiente de la glucosa) gip para el tratamiento de trastornos metabolicos y obesidad | |
| AR094180A1 (es) | Derivados de exendina-4 | |
| JP2016512213A5 (https=) | ||
| NZ621196A (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
| AR065349A1 (es) | Coagonistas del receptor de glucagon/glp-1 | |
| CL2020003292A1 (es) | Péptido que consiste en la secuencia de aminoácidos de seq id no: 2; anticuerpo que reconoce dicho péptido; receptor de linfocito t; célula hospedadora; linfocito t activado; composición farmacéutica; uso; y kit (divisional de la solicitud no. 201802969) | |
| AU2025205152A1 (en) | Acylated calcitonin mimetics | |
| ES2993282T9 (en) | Method of using a gip/glp1 co-agonist for diabetes | |
| KR20230084337A (ko) | 인슐린 저항성에 대한 개선된 펩티드 약제 |